Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5827 - Implications of Thymidylate Synthase gene polymorphisms, KRAS and BRAF mutations in the survival of patients with colorectal cancer treated with adjuvant chemotherapy

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Targeted Therapy

Tumour Site

Colon and Rectal Cancer

Presenters

Anastasios Ntavatzikos

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

A. Ntavatzikos1, A. Spathis2, P. Patapis3, G. Peros4, I. Panayiotides5, I. Papadopoulos4, A. Koumarianou1

Author affiliations

  • 1 Hematology Oncology Unit, Fourth Department Of Internal Medicine, Athens Greece, Attikon University Hospital, 12462 - Athens/GR
  • 2 Dept Of Cytopathology, Attikon University Hospital, 12462 - Athens/GR
  • 3 Third Dept Of Surgery, Attikon University Hospital, 12462 - Athens/GR
  • 4 Fourth Department Of Surgery, Attikon University Hospital, 12462 - Athens/GR
  • 5 Pathology, Attikon University Hospital, 12462 - Athens/GR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5827

Background

Fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer (CRC) is associated with a reduction of recurrence in only 25% of patients (pts) with stage III disease. The aim of this study was to investigate thymidylate synthase (TYMS) gene polymorphisms, KRAS and BRAF as possible factors affecting therapeutic outcome in pts with stage III CRC.

Methods

Formalin-fixed paraffin-embedded tissues of 130 consecutive pts treated with FABC between 2005-2007 were analysed with PCR for the detection of TYMS polymorphisms, mKRAS and mBRAF. Patients were classified into three groups of 5’UTR TYMS polymorphisms according to the predicted expression profile (high, medium and low). Based on the presence or absence of the 3’UTR polymorphism ins/LOH pts were allocated into two groups (high and low risk). Cox regression models examined factors associated with survival outcome.

Results

The 5-year DFS and OS rate was 61.6% and 73.9% respectively. Patients who had tumors with 5’UTR polymorphisms of intermediate TYMS expression profile (2RG/3RG, 2RG/LOH, 3RC/LOH) when compared to those with low (2RG/2RG, 2RG/3RC, 3RC/3RC) or high expression (3RG/3RG, 3RG/LOH, 3RG/3RC) had lower risk for relapse (HR 0.320, p = 0.02 and HR 0.343, p = 0.013 respectively) and death (HR 0.368, p = 0.031 and HR 0.394, p = 0.029 respectively). The 3’UTR polymorphism ins/LOH was independently associated with increased risk for disease recurrence (p = 0.001) and death (p = 0.005). Presence of mBRAF (3.8% pts) was associated with an increased risk of death (HR 4.500, p = 0.022), whereas mKRAS (39% of pts) was not found to correlate with survival.

Conclusions

The group of TYMS polymorphisms 2RG/3RG, 2RG/LOH, 3RC/LOH, the absence of ins/LOH and absence of mBRAF were associated with better prognosis of pts with early stage CRC. Mutated KRAS was not found to affect relapse or risk of death in the adjuvant setting. Further prospective studies investigating the role of TYMS polymorphisms and mBRAF are warranted to identify pts who could benefit from 5FU-based cytotoxic chemotherapy.

Clinical trial identification

Legal entity responsible for the study

Anna Koumarianou.

Funding

National and Kapodistrian University of Athens.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.